These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Expert commentary: the safety of fibrates in lipid-lowering therapy. Brown WV Am J Cardiol; 2007 Mar; 99(6A):19C-21C. PubMed ID: 17368273 [TBL] [Abstract][Full Text] [Related]
4. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Barter PJ; Rye KA Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):39-46. PubMed ID: 17717290 [TBL] [Abstract][Full Text] [Related]
5. Is it time to stop treating dyslipidaemia with fibrates? Benatar JR; Stewart RA N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928 [TBL] [Abstract][Full Text] [Related]
6. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Staels B; Maes M; Zambon A Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776 [TBL] [Abstract][Full Text] [Related]
8. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [TBL] [Abstract][Full Text] [Related]
9. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
10. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Vergès B Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910 [TBL] [Abstract][Full Text] [Related]
11. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Preiss D; Sattar N Clin Endocrinol (Oxf); 2009 Jun; 70(6):815-28. PubMed ID: 19067719 [TBL] [Abstract][Full Text] [Related]
12. Safety considerations with fibrate therapy. Davidson MH; Armani A; McKenney JM; Jacobson TA Am J Cardiol; 2007 Mar; 99(6A):3C-18C. PubMed ID: 17368275 [TBL] [Abstract][Full Text] [Related]
13. Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics. Ong HT; Cheah JS Chin Med J (Engl); 2008 Aug; 121(16):1588-94. PubMed ID: 18982874 [TBL] [Abstract][Full Text] [Related]
14. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. Paumelle R; Staels B Trends Cardiovasc Med; 2008 Apr; 18(3):73-8. PubMed ID: 18436144 [TBL] [Abstract][Full Text] [Related]
15. [Favorable effects of decreasing lipids in patients with diabetes mellitus]. Gouni-Berthold I; Krone W Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581 [TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Dahabreh IJ; Economopoulos K Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649 [TBL] [Abstract][Full Text] [Related]
18. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials. Saha SA; Molnar J; Arora RR J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946 [TBL] [Abstract][Full Text] [Related]
19. [The best of epidemiology and cardiovascular prevention in 2006]. Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. Jones PH Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]